IL4 and B-cell chronic lymphocytic leukemia: STAT inhibition normalized the effects of IL‐21 and IL‐4 on venetoclax resistance to the level of 3T40‐activated CLL cells (Fig. 6A,B), confirming the enhancing and attenuating effects of IL‐4 and IL‐21, respectively.